![](/images/graphics-bg.png)
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial
Joint Authors
Kimura, Takefumi
Maruyama, Masafumi
Tanaka, Naoki
Kubota, Daisuke
Miyajima, Masayuki
Tokutake, Koujiro
Imai, Ryujiro
Fujisawa, Toru
Mori, Hiromitsu
Matsuda, Yoshiaki
Wada, Shuichi
Horiuchi, Akira
Kiyosawa, Kendo
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-02-28
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Background.
A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H.
pylori eradication therapies.
We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one.
Methods.
This randomized controlled trial was designed to assign 141 patients with H.
pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days).
Primary endpoints were eradication rates and adverse events.
Results.
Seventy of 72 patients in VPZ group and 63 of 69 patients in PPI group completed the treatment after 7 days.
The eradication rate was significantly higher in VPZ group than PPI group by intention-to-treat analysis (95.8% versus 69.6%, P=0.00003, 95% confidence interval [CI] 88.3-99.1% versus 57.3-80.1%) and per-protocol analysis (95.7% versus 71.4%, P=0.0002, 95% CI 88.0-99.1% versus 58.7-82.1%).
The incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group, P=0.15).
Conclusion.
VPZ-based regimen is more useful than that PPI-based regimen as a first-line H.
pylori eradication therapy.
American Psychological Association (APA)
Maruyama, Masafumi& Tanaka, Naoki& Kubota, Daisuke& Miyajima, Masayuki& Kimura, Takefumi& Tokutake, Koujiro…[et al.]. 2017. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Canadian Journal of Gastroenterology and Hepatology،Vol. 2017, no. 2017, pp.1-7.
https://search.emarefa.net/detail/BIM-1141415
Modern Language Association (MLA)
Maruyama, Masafumi…[et al.]. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Canadian Journal of Gastroenterology and Hepatology No. 2017 (2017), pp.1-7.
https://search.emarefa.net/detail/BIM-1141415
American Medical Association (AMA)
Maruyama, Masafumi& Tanaka, Naoki& Kubota, Daisuke& Miyajima, Masayuki& Kimura, Takefumi& Tokutake, Koujiro…[et al.]. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Canadian Journal of Gastroenterology and Hepatology. 2017. Vol. 2017, no. 2017, pp.1-7.
https://search.emarefa.net/detail/BIM-1141415
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141415